Clinical Trial

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Study acronym: PRIOR
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes. Participants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-01.
Trial Details
NCT Number NCT07263490
Lead Sponsor Copenhagen University Hospital, Hvidovre
Collaborators: Ferring Pharmaceuticals, Gedeon Richter Ltd.
Conditions Pre-eclampsia, Oocyte Donation, Pre-Eclampsia; Complicating Pregnancy, Pre-Eclampsia; Mild, Pre-Eclampsia, Severe, Pre-eclampsia or Eclampsia With Pre-existing Hypertension, ART, Neonatal Morbidity +7 more
Enrollment 462 participants
Start Date 2024-10-21
Primary Completion 2027-10-31 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13